Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 449

Sort by

Sort Order Select

Journal Articles

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, Anita D’Souza, Anannya Patwari, Andrew Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan O. Schönland, Suzanne Lentzsch, Eli Muchtar

Blood (2024) 144 (25): 2613–2624.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma

Nadine Abdallah, Matthew Rees, Supriya Gupta, Mohammed Elhaj, Radhika Bansal, Terri Menser, Gavin Schaeferle, Joselle Cook, Taxiarchis Kourelis, Rahma M Warsame, Wilson I. Gonsalves, Prashant Kapoor, Francis Buadi, Suzanne R Hayman, David Dingli, Morie A. Gertz, Yi Lin, Shaji Kumar

Blood (2024) 144 (Supplement 1): 4695.

https://doi.org/10.1182/blood-2024-211768

Published: 2024

Journal Articles

Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization

Blood (2024) 144 (Supplement 1): 5047.

https://doi.org/10.1182/blood-2024-199229

Published: 2024

Journal Articles

Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Blood (2024) 144 (Supplement 1): 2372.

https://doi.org/10.1182/blood-2024-210474

Published: 2024

Journal Articles

A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States

Morie A. Gertz, Heather J. Landau, Vaishali Sanchorawala, Manisha Bhutani, Jeffrey A. Zonder, Michael Rosenzweig, Gray Magee, Cynthia Campos, Irina Yermilov, Eunice Chang, Michael S. Broder, Preeti Bajaj

Blood (2024) 144 (Supplement 1): 3665.

https://doi.org/10.1182/blood-2024-206132

Published: 2024

Journal Articles

Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis

Blood (2024) 144 (Supplement 1): 2400.

https://doi.org/10.1182/blood-2024-209102

Published: 2024

Journal Articles

Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 83.

https://doi.org/10.1182/blood-2024-202098

Published: 2024

Journal Articles

Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience

Blood (2024) 144 (Supplement 1): 1981.

https://doi.org/10.1182/blood-2024-208294

Published: 2024

Journal Articles

Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease

Blood (2024) 144 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2024-208790

Published: 2024

Journal Articles

Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Blood (2024) 144 (Supplement 1): 5149.

https://doi.org/10.1182/blood-2024-210932

Published: 2024

Journal Articles

Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients

Nadia Toumeh, Matthew James Rees, Morie A. Gertz, Angela Dispenzieri, Binoy Yohannan, Suheil Albert Atallah-Yunes, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, Suzanne R Hayman, Francis Buadi, David Dingli, Joselle Cook, Rahma M Warsame, Moritz Binder, Wilson I. Gonsalves, S. Vincent Rajkumar, Shaji Kumar, Eli Muchtar

Blood (2024) 144 (Supplement 1): 3308.

https://doi.org/10.1182/blood-2024-202059

Published: 2024

Journal Articles

Proteomic Determinants of Renal Organ Response in AL Amyloidosis

Matthew James Rees, Eli Muchtar, Suheil Albert Atallah-Yunes, Surendra Dasari, Nelson Leung, Morie A. Gertz, Angela Dispenzieri, Ellen McPhail, Shaji Kumar, Emilie Anderson, Christopher Dick, Taxiarchis Kourelis

Blood (2024) 144 (Supplement 1): 3305.

https://doi.org/10.1182/blood-2024-201168

Published: 2024

Journal Articles

Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes

Blood (2024) 144 (Supplement 1): 4728.

https://doi.org/10.1182/blood-2024-208736

Published: 2024

Journal Articles

Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia

Blood (2024) 144 (Supplement 1): 3315.

https://doi.org/10.1182/blood-2024-200267

Published: 2024

Journal Articles

Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4716.

https://doi.org/10.1182/blood-2024-211755

Published: 2024

Journal Articles

Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma

Jacob T Shreve, Michael D Howe, Emmanuel Contreras Guzman, Charalampos Charalampous, Wilson I. Gonsalves, Francis Buadi, Taxiarchis Kourelis, Suzanne R Hayman, Morie A. Gertz, Rafael Fonseca, S. Vincent Rajkumar, Surendra Dasari, Matthew P. Thorpe, Stephen Broski, Shaji Kumar, Moritz Binder

Blood (2024) 144 (Supplement 1): 4711.

https://doi.org/10.1182/blood-2024-202022

Published: 2024

Journal Articles

Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy

Blood (2024) 144 (Supplement 1): 7165.

https://doi.org/10.1182/blood-2024-211111

Published: 2024

Journal Articles

Autologous Stem Cell Transplantation for Multiple Myeloma Patients Whose Myeloma Defining Event Was Slim

Iuliana Vaxman, Shaji Kumar, Inbar Cohen, Shai O. Shimony, Angela Dispenzieri, Francis Buadi, David Dingli, Martha Lacy, Eli Muchtar, Prashant Kapoor, William J. Hogan, Suzanne R Hayman, Nelson Leung, Wilson I. Gonsalves, Taxiarchis Kourelis, Rahma M Warsame, Morie A. Gertz

Blood (2024) 144 (Supplement 1): 7078.

https://doi.org/10.1182/blood-2024-205062

Published: 2024

Journal Articles

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2024) 144 (Supplement 1): 7589.

https://doi.org/10.1182/blood-2024-210586

Published: 2024

Journal Articles

TP53 -Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Kevin Hung, Aref Al-Kali, Carla Toop, Mrinal M. Patnaik, Zoe Price, Taxiarchis Kourelis, Daniel Thomas, Morie A. Gertz, Hossein Anani, Wilson I. Gonsalves, Chung Hoow Kok, Ayalew Tefferi, Devendra Hiwase, Mithun V Shah

Blood (2024) 144 (Supplement 1): 4594.

https://doi.org/10.1182/blood-2024-211931

Published: 2024

NARROW

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma

Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization

Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States

Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis

Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience

Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease

Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients

Proteomic Determinants of Renal Organ Response in AL Amyloidosis

Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes

Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia

Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma

Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma

Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy

Autologous Stem Cell Transplantation for Multiple Myeloma Patients Whose Myeloma Defining Event Was Slim

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

TP53 -Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only